Skip to main content
Premium Trial:

Request an Annual Quote

Arna Genomics Raises $3.5M In Series A Financing

NEW YORK – Arna Genomics said over the weekend that it has raised $3.5 million in a Series A funding round led by Xploration Capital.

The Wilmington, Delaware-based startup will use the funds for clinical validation trials in Europe, the US, and the Commonwealth of Independent States for its Arna Breast diagnostic test, which detects nucleic acid fragments in a patient's plasma sample. The firm also plans to expand operations to the Indian and Chinese markets.

Arna's liquid biopsy assay measures the circulating cell-free DNA in a breast cancer patient's plasma sample and plasma enzyme activity. The firm aims to apply its methods for early-stage cancer detection and monitoring patient response to therapy.

The company added that an unpublished proof-of-concept study conducted with Sechenov University has demonstrated that the test has accuracy of greater than 90 percent.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.